These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 7695715)

  • 1. Cost-effectiveness analyses.
    Tilson H; Kotsanos JG
    N Engl J Med; 1995 Jan; 332(2):124; author reply 124-5. PubMed ID: 7695715
    [No Abstract]   [Full Text] [Related]  

  • 2. The journal's policy on cost-effectiveness analyses.
    Kassirer JP; Angell M
    N Engl J Med; 1994 Sep; 331(10):669-70. PubMed ID: 7695687
    [No Abstract]   [Full Text] [Related]  

  • 3. [Roaming through methodology. XIX. Cost-effectiveness ratios].
    Rutten FF
    Ned Tijdschr Geneeskd; 2000 Jul; 144(27):1311-4. PubMed ID: 10918910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analyses in obstetrics & gynecology. Evaluation of methodologic quality and trends.
    Subak LL; Caughey AB; Washington AE
    J Reprod Med; 2002 Aug; 47(8):631-9. PubMed ID: 12216429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of finder's fees in clinical research.
    Maher EA
    CMAJ; 1994 Jan; 150(2):252-6. PubMed ID: 8287347
    [No Abstract]   [Full Text] [Related]  

  • 6. Financial conflict of interest in medical research: overview and analysis of institutional controls.
    Henderson JA; Smith JJ
    Food Drug Law J; 2003; 58(2):251-67. PubMed ID: 12866557
    [No Abstract]   [Full Text] [Related]  

  • 7. Conflict of interest in medical research and development.
    Ward S
    Semin Perioper Nurs; 1993 Jul; 2(3):197-201. PubMed ID: 8044171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ezetimibe=cost effectiveness. Science or a debate contribution from MSD?].
    Lindberg M
    Ugeskr Laeger; 2008 Sep; 170(38):2987; author reply 2988. PubMed ID: 18816890
    [No Abstract]   [Full Text] [Related]  

  • 9. The benefits and threats of research partnerships with industry.
    Duval G
    Crit Care; 2005 Aug; 9(4):309-10. PubMed ID: 16137365
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Kobelt G
    Rheumatology (Oxford); 2008 Oct; 47(10):1589-90; author reply 1590; discussion 1590-1. PubMed ID: 18710898
    [No Abstract]   [Full Text] [Related]  

  • 11. AAOHN advisory: cost benefit and cost effectiveness analyses.
    Widfelt AK
    AAOHN J; 1996 Jan; 44(1):8A-8B. PubMed ID: 8694974
    [No Abstract]   [Full Text] [Related]  

  • 12. [Research sponsored by the industry benefits scientific progress].
    Raaijmakers JA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(32):1768. PubMed ID: 16948236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data.
    Willan AR; Briggs AH; Hoch JS
    Health Econ; 2004 May; 13(5):461-75. PubMed ID: 15127426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis in pathology.
    Raab SS
    Clin Lab Med; 1999 Dec; 19(4):757-71, v-vi. PubMed ID: 10572713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents.
    Rinfret S; Schampaert E
    CMAJ; 2007 May; 176(11):1611-2. PubMed ID: 17515589
    [No Abstract]   [Full Text] [Related]  

  • 16. Policy of the American Society of Gene Therapy on financial conflict ofinterest in clinical research.
    Woo SL
    Mol Ther; 2000 May; 1(5 Pt 1):383-4. PubMed ID: 10979736
    [No Abstract]   [Full Text] [Related]  

  • 17. Using propensity scores to estimate the cost-effectiveness of medical therapies.
    Indurkhya A; Mitra N; Schrag D
    Stat Med; 2006 May; 25(9):1561-76. PubMed ID: 16158412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RE: a rebuttal: secret ties to industry and conflicting interests in cancer research.
    Hardell L; Walker MJ; Walhjalt B; Friedman LS; Richter ED
    Am J Ind Med; 2007 Sep; 50(9):697-8; author reply 699-700. PubMed ID: 17683064
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-inclusive evaluation: a banquet of approaches for including costs, benefits, and cost-effectiveness and cost-benefit analyses in your next evaluation.
    Yates BT
    Eval Program Plann; 2009 Feb; 32(1):52-4. PubMed ID: 18977532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putting a price on research reading.
    Butler D
    Nature; 1999 Sep; 401(6751):311-2. PubMed ID: 10517617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.